Functional Precision Oncology, a new compass for cancer care | Apricot Bio

About this episode

The episode discusses functional precision oncology and its implications for cancer treatment with the founders of Apricot Bio.

In this special panel episode recorded in Zurich, the founders of Apricot Bio, Michael Zering (CEO), Lucas Pelkmans (Scientific Founder), and Independent Professor Andreas Wicki from the University of Zurich explore the new field of functional precision oncology—an approach that goes beyond genomics to test how living cancer cells actually respond to treatment. The conversation covers the limits of genetic diagnostics, the promise of ex vivo drug testing, AI-driven decision-making, and how smarter trial design could transform cancer care. The panel also dives into Switzerland’s biotech ecosystem, venture capital realities, and what it takes to bring high-risk, high-impact science from the lab to the clinic.

People in this episode

Guests: Michael Zering, Lucas Pelkmans, Andreas Wicki

Topics covered

• functional precision oncology
• cancer care
• genomics
• ex vivo drug testing
• AI-driven decision-making
• biotech ecosystem
• venture capital

Keywords

• cancer
• oncology
• biotech
• drug testing
• AI
• venture capital
• Switzerland

Mentioned in this episode

Organizations: Apricot Bio, University of Zurich

Places: Zurich, Switzerland

More episodes of Nucleate Podcast

• Leading Mission-Driven Biotechs | Jodie Morrison, CEO of Q32 Bio · June 4, 2026 · 1h 6m
• From Genomics to Deal-Making: How Science Becomes a Company | Laurence Reid, Biotech Entrepreneur · March 24, 2026 · 1h 36m
• Negotiating Intellectual Property, Staying Focused, and Making the Most of Mentors with Michal Preminger, Board Member at MassBio · March 10, 2026 · 1h 8m
• How Turbine Accelerates Drug Discovery with AI Simulation | Szabi Nagy, CEO and Co-Founder of Turbine · February 24, 2026 · 57 min
• The Science of Stem Cells and Social Impact: Inside Ovelle with Merrick Smela and Travis Potter · February 10, 2026 · 50 min
• Inside TechBio Investing | Claire Smith, Partner at Springtide VC · January 27, 2026 · 1h 3m